Login to Your Account

In The Clinic NEWS

As investors waited Wednesday afternoon for Sarepta Therapeutics Inc.'s second-quarter earnings, news of a MAP with Clinigen Group plc's Idis division for Exondys 51 in DMD had Wall Street speculating that the deal would add to fiscal-year 2017 guidance of more than $95 million.

HONG KONG – Cstone Pharmaceuticals Co. Ltd. has received the go-ahead from the CFDA to conduct clinical trials with its investigational agent, CS-1001, making it the first company in China to successfully have a fully human, full-length anti-PD-L1 monoclonal antibody enter clinical development.

Cymabay Therapeutics Inc. said positive interim phase II results for its PBC treatment, seladelpar, won FDA support for extended dosing of the drug, a key go-ahead enabling the company to plan its phase III program.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: